Innovation and Overcoming Limitations in HIV Treatment Paradigm

Existing Antiretroviral Therapy (ART) has primarily focused on suppressing viral replication, managing HIV as a chronic condition. However, it faces limitations such as the inconvenience of lifelong medication, side effects, and the risk of drug resistance. The emergence of drugs like Lenacapavir, developed by Gilead Sciences (GILD), has significantly improved treatment convenience. The market is now shifting towards a paradigm of functional cure, aiming to completely eliminate the virus from the body, moving beyond simple management.

Gene Editing Challenges in Eliminating Latent Reservoirs

A major obstacle in achieving a cure is the presence of latent reservoirs, where immune cells harbor dormant viruses. Excision BioTherapeutics is conducting a Phase 1/2 clinical trial of EBT-101, a gene therapy utilizing CRISPR-Cas9 technology to address this. EBT-101 employs an Adeno-Associated Virus (AAV9) vector to directly cleave viral genes. Although all patients in the early clinical trial experienced viral rebound after treatment discontinuation, some maintained viral suppression for 16 weeks, demonstrating potential.

Combination Strategies with Immune Modulation and Vaccine Therapies

In addition to gene editing, Gilead is diversifying its cure portfolio by securing various immune-based therapies. Phase 2a clinical trial results have been announced for the combination of HTI therapeutic vaccine from AELIX Therapeutics and Vesatolimod, a Toll-like Receptor 7 (TLR7) agonist from Gilead. The results showed that 33.3% of patients in the vaccine group maintained viral suppression for six months after treatment interruption. Furthermore, Caring Cross's dual-target CAR-T cell therapy has also shown positive treatment signals in early clinical trials, highlighting the emergence of diverse immune therapies.

Global Health Finance Shifts and Market Impact

The global HIV therapeutics market is estimated at approximately $40 billion to $41.5 billion in 2026, with Gilead holding a dominant position with its Biktarvy, generating $14.3 billion in annual revenue. However, the temporary suspension of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) in January 2025 has significantly reduced global HIV-related health support. This funding shortage negatively impacts treatment access, particularly in developing countries, and lowers overall viral suppression rates. Therefore, pharmaceutical companies are focusing on commercializing long-acting, twice-yearly injectable prevention and treatment regimens to reduce the burden of high-cost, continuous prescriptions.

Long-Term Industrial Prospects for Curative Treatments

The commercialization of innovative technologies such as gene therapy and vaccines can address the long-term drug cost burden with one-time or short-term treatments, which is beneficial for healthcare finance. However, due to the nature of curative therapies, initial treatment costs may be very high, making it crucial to overcome health insurance reimbursement barriers. Nevertheless, if the chronic disease market transitions to a cure market, the corporate value of leading companies such as Gilead and Excision, which have secured related platform technologies, is likely to increase in the long term. This will also provide new commercial benchmarks for companies developing treatments for other chronic viral diseases.